Lung Cancer | Specialty

Durvalumab/Tremelimumab Combo Explored in Lung Cancer Trial

February 5th 2016

With the approval of a dual checkpoint blockade treatment in melanoma, researchers hope to have similar success in a phase III trial that combines a PD-L1 inhibitor and CTLA-4 antibody in patients with non–small cell lung cancer.

Distinct Genomic Differences Evident in Younger Patients With Lung Cancer

February 5th 2016

Clinical trial findings have implications for expanding the use of genomic testing—and thereby potentially increasing treatment options—for the younger lung cancer population.

Osimertinib Approved in Europe for EGFR T790M-Mutant NSCLC

February 3rd 2016

The European Commission has granted a conditional marketing authorization to osimertinib for patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with EGFR TKI.

EGFR Inhibitors Continue March in Mutated NSCLC

January 29th 2016

After a rocky start, drugs that inhibit the epidermal growth factor receptor pathway have evolved into a new treatment paradigm for patients with non–small cell lung cancer whose tumors harbor EGFR mutations.

PD-1 Inhibitors Make Tremendous Impact in NSCLC, But Questions Remain

January 28th 2016

Renato Martins, MD, discusses what questions still remain regarding PD-L1 as a biomarker, sequencing, and how nivolumab and pembrolizumab compare head-to-head in non–small cell lung cancer.

Expert Assesses Atezolizumab in NSCLC

January 28th 2016

Chandra P. Belani, MD, discusses the impact of clinical trials examining atezolizumab and the role of PD-L1 as a predictive and prognostic biomarker for response to the agent in non–small celll lung cancer.

Vaccine Strategy for Biomarker in NSCLC Reaches Phase III Study

January 27th 2016

An emerging vaccine strategy, of TG4010 immunotherapy and first-line chemotherapy, that could target a potential new biomarker in patients with advanced non-small cell lung cancer (NSCLC) has successfully reached a phase III clinical trial, researchers noted.

Emerging Targets in NSCLC Treatment

January 13th 2016

Subtypes in NSCLC: BRAF and RET

January 13th 2016

Approval of Third-Generation TKIs for EGFR-Targeted Therapies

January 13th 2016

Next-Generation ALK Inhibitors for NSCLC

January 13th 2016

Ceritinib in Crizotinib-Resistant NSCLC

January 13th 2016

Crizotinib for ALK-Rearranged NSCLC

January 13th 2016

EGFR Inhibition and Resistance Mechanisms

January 13th 2016

Current Practices in NSCLC Genetic Testing

January 13th 2016

Therapeutic Classes in Advanced NSCLC

January 13th 2016

NSCLC Emerging as a Growing Problem Among Never-Smokers

January 13th 2016

A substantial—and potentially growing—proportion of patients with non–small cell lung cancer are people who never, or only rarely, smoked.

Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC

January 7th 2016

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

ESMO Asia Congress, Alcohol-Free Docetaxel Approved, and More

December 31st 2015

FDA Approves Alcohol-Free Docetaxel Formulation

December 28th 2015

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.